Clinical Research Centre
Hospital Sultan Ismail
Johor Bahru, Johor
WhoWe Are
Established in January 2012, the Clinical Research Centre Hospital Sultan Ismail Johor Bahru (CRC HSIJB) supports the hospital's growing research activities as part of the CRC network, which includes 36 hospital CRCs across Malaysia. Located on the second floor of the main building, CRC HSIJB features a reception area, 15 workstations, a consultation room, a meeting room, a store room, and four documentation areas. We offer training in Good Clinical Practice, protocol design, and sample size calculation, and provide consultations to assist researchers with NMRR registration, grant applications, statistical analysis, and publication.
OurTeam
InvestigatorsHighlight
Head of CRC, Clinical Oncologist, Hospital Sultan Ismail, Johor Bahru
Email: nehc_88@yahoo.com
MD, MCO (UM)
Areas of interest: Lung cancer, gynaecological cancer, breast cancer
Awards and achievements:
- Chairperson , Johor Oncology Meeting , Hospital Sultan Ismail - 2024
- Vice Chairperson, Johor Oncology Meeting, Hospital Sultan Ismail - 2023
- Chairperson, Masterclass in Systemic Cancer Therapy, University Malaya - 2020
- Chairperson, Palliative workshop, Hospital Sultan Ismail - 2017
I completed my medical degree from University Malaysia Sabah in 2010, following which, I pursued and completed my specialty training in Clinical Oncology at University Malaya in 2022. At year 2024, I completed my FRCR exam and admitted as fellow in Royal College of Radiologist. I was certified with Good Clinical Practice in 2015, since then I have been involved as a sub-investigator in various clinical studies which focus on ovarian cancer and thyroid cancer during my master training program. I gained valuable experiences from my lecturer and colleague. I have been involved in conferences, abstract presentations, and publications focusing on key areas of oncology. At present, I am the lead investigator for several new industry-sponsored studies, which have given our patients access to cutting-edge treatments. As an oncologist, my goal is to offer the most up-to-date, personalized care backed by strong clinical evidence.
Research Highlights
- A Multicenter, Randomized, Double blind, phase 2, basket study of MK4280A, a Coformulation of Favezelimab ( M-4280) with Pembrolizumab ( MK-3475) in Selected Solid Tumour( Skin and endometrium cancer )
- A Phase III Randomised, Double-blind, Multicentre Study toCompare the Efficacy, Safety, Pharmacokinetics, andImmunogenicity between SB27 (proposed pembrolizumabbiosimilar) and Keytruda in Subjects with Metastatic NonsquamousNon-small Cell Lung Cancer
- A phase 3 study to evaluate zimberelimab (AB122) combined with Domvanalimab( AB154) compared to Pembrolizumab in front line, PD L-1 High, locally advanced or Metastatic Non Small Cell Lung Cancer (ARC-10)
- Masterkey Atlas Genomic study
- A Phase III, randomized, Double- Blind, Placebo - Controlled Study Evaluating The Efficacy And Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patient with PIK3CA - Mutant, Hormone Receptor, HER-2 Negative Locally Advanced Or Metastatic Breast Cancer (INAVO)
- A Phase III, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non Small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8)
- Z100 trial for cervical cancer
Recent Publications
Prospective Study On Acute Toxicity Associated With Hypofractionated Breast Radiotherapy Based On The UK Fast-Forward Protocol
A case of primary pulmonary hepatoid adenocarcinoma
An Overview of Pazopanib in Metastatic Renal Cell Carcinoma (mRCC) in Ministry of Health (MOH), Malaysia - A Multicentre Experience
A One Year Review Of Drug Resistant Pattern In Pulmonary Tuberculosis
Deputy Head of CRC, Geriatrician, Hospital Sultan Ismail, Johor Bahru
Email: drlimht@hsi.gov.my
MBBAOBCh (University College of Cork, Ireland ), MRCP (Royal College of Physicians, UK), Fellowship in Geriactric Medicine (KKM)
Areas of interest: Orthogeriatric services and fracture liaison service. Multidisciplinary care for older adults.
Awards and achievements:
- Co-scientific chair and speaker, Fragility Fracture Network Malaysia Annual Congress - 2023
- Co-scientific chair and speaker, Geriatric Workshop, Hospital Sultan Ismail - 2023
- Chairperson, Malaysian Congress of Geriatric Medicine - 2022
- Co-scientific chair and speaker, Geriatric Workshop, Hospital Sultan Ismail - 2023
- Chairperson, MyFalls 1st Scientific Meeting ‘Multidisciplinary Approach in Falls Prevention - 2022
- Chairperson in 1st World Congress on Falls and Postural Stability - 2019
Dr. Lim practices as a physician and geriatrician. He has vast interest in the care of geriatric and healthcare improvement projects.
Research Highlights
- SAPPHIRE
- Outcomes and impact of fragility fracture among geriatric patients who underwent hip surgery in Hospital Kuala Lumpur
- Process mapping of hip fracture orthogeriatric care: experience from a tertiary hospital in Malaysia
- Multi-Center Validation of Pain Assessment in Advanced Dementia (PAINAD) Scale in Malaysia
- A Retrospective Observational Analysis on the Characteristics of Injurious Inpatient Fallers in Kuala Lumpur General Hospital from 2014 till 2019
Recent Publications
Prevalence of ventilator associated pneumonia in Hospital Tuanku Ja’afar Seremban
Case report: cardiac tamponade a rare presentation of Hashimoto’s thyroiditis
A two-year review of dengue mortalities in Malaysian tertiary hospital: obesity as major comorbidity
Polypharmacy among cognitively impaired elderly patients
Post stroke care survey in a secondary hospital in Malaysia
Project Highlights
| NMRR-23-01942-D0U | Pharmacists' Confidence and Competence in Conducting Research and Their Perception towards The Research Impact in Johor Government Healthcare Facilities |
| NMRR ID-22-00773-V1N | Management of Displaced Mandibular Fracture in an Infant - A Case Report |
| NMRR ID-22-01313-RED | Barriers to Systemic and Biologic Treatments for Patients with Moderate-To-Severe Psoriasis among Dermatologists in Malaysia. |
| NMRR ID-23-01556-HOD | An Assessment of Knowledge in Haemophilia and The Dental Management among Government Paediatric Dental Health Care Providers in Malaysia |
| NMRR ID-23-00002-J8S |
Development and Content Validation of Comprehensive Oral Care for Paediatric Cancer Patient Knowledge Assessment Tools (COCPCP) for Usage among Healthcare Providers |
| NMRR ID-23-02327-BG7 | The Obstetric Outcomes of Morbid Obesity in Trial of Labor After Caesarean Section With Spontaneous Labor |
| NMRR ID-23-01278-GDQ | Can H2-Antagonist be Omitted Safely from the Premedication Regimen for Paclitaxel Administration? A Malaysian Multi-Centre Cohort study |
| NMRR ID-23-00222-0A5 | Cutaneous Manifestations of Connective Tissue Diseases: Association with Antinuclear Antibodies and Impact on Quality of Life |
| NMRR-23-00815-NNF | Treatment Outcome and Predictors of Frequent Relapses and Steroid Dependent in Children with Steroid Sensitive Nephrotic Syndrome |
| NMRR-23-00444-0HB | A Season of Acute Kidney Injury Post Breast Augmentation. |
| NMRR-23-00173-YRY |
Empathy as a Predictor for Mild Autism Spectrum Disorder in Children |
| NMRR-23-00382-9PG | Pharmacovigilance of Nirmatrelvir/Ritonavir: Real Experience in Malaysian Primary Health Care Setting |
| NMRR-23-00598-GDS | A Multi-Centre Cross-Sectional Study: Knowledge, Attitude, and Practice (KAP) of Flood Disaster Management among Emergency Medicine and Trauma Services Personnel in Johor. |
| NMRR-23-01413-IZP | Association of ENA with Lupus Nephritis |
| NMRR-23-00386-ERC | Management Of Lateral Synechiae Associate With Cleft Palate - A Case Report |
| NMRR-23-02392-D8M | Management of Comminuted Mandibular Fracture in Young Children - A Case Report |
| NMRR-23-02774-I0G | Genetic Association of Single Nucleotide Polymorphisms DPF3 and CAT-262 Genes with Infertility in Malaysian Males |
| NMRR-23-00343-TPB | Housemanship Completion among Contract House Officers (Cohort 1 to 7): Associated Factors & Related Issues. |
| NMRR-23-02421-ZZS | A Case Report of Acute Osteomyelitis over Right Mandible |
| NMRR-23-01296-LPX | Cochlear Implantation in Severe to Profound Hearing Loss for Pre-Lingual Children who Passed Newborn Hearing Screening |
| NMRR-23-01119-S1M | Perspective of Children with Autism Spectrum Disorder Receiving Cochlear Implants: Sharing Experience from Single Institution |
| NMRR-23-00552-JOR | Prevalence of a Homologous Recombinant Deficiency (HRD) Signature in Asian Metastatic Breast Cancer Patients (TENOR-P) |
| NMRR-23-01107-JVW | Seropositivity of Rickettsioses in Malaysia from 2016 to 2021 |
| NMRR-23-01321-I6P |
Use Of CAM-ICU in Care of Critically Ill Patient Hospital Sultan Ismail Johor Bahru |
| NMRR-23-01153-NFX | Diagnostic Accuracy of Tuning Fork Weber Test and Audiometric Weber Test in School-aged Children with Conductive Hearing Loss |
| NMRR-23-02501-XNT | Factors Influencing Non-Adherence to Chemotherapy Treatment among Breast Cancer Patient at Institut Kanser Negara |
| NMRR-23-01194-N6D | Mitochondrial Carnitine Palmitoyltransferase IA Deficiency Associated with Novel Mutations |
| NMRR-23-02147-Z69 |
Factors Associated with Hospital Acquired Pressure Injury (HAPI) among Inpatient in Johor Public Hospitals |
| NMRR-23-01661-DBV | Comparison of Clinical Characteristics and Outcome of Methicillin Sensitive Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus Bacteraemia in Malaysia |
| NMRR-23-02726-OD4 |
Effectiveness of Face-To-Face and Virtual Counseling among Diabetic Patients in PKD Kuala Terengganu |
| NMRR-23-02492-5VX | MySCI 2023: A Survey on Lived Experience of People Living with Spinal Cord Injury in Malaysia. |
| NMRR-23-01312-4NS | Recognizing and Combating Multiple Myeloma in Pregnancy |
| NMRR-23-02470-DWE |
Technical Evaluation of Automated Slidemaker in Hematology Unit, Pathology Department, Hospital Sultan Ismail |
| NMRR-23-02666-SBS |
Analysis of Perception of Healthcare Worker that Contributes to Sample Rejection at Hematology Unit of Pathology Laboratory in Hospital Sultan Ismail (HSI) |
| NMRR-23-02729-EWX | Pharmacy Value Added Services: Analysis of User Preference and Cost |
| NMRR-23-01936-LCI |
A Randomized Control Trial: The Role of Alkalinising Agent Used in Paediatric Urinary Tract Infection (UTI) |
| NMRR-23-02467-3JV | Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia (EVOS): A multicentre, Randomised, Open-Label Clinical Trial Study |
| NMRR-23-02009-KW0 |
Survival Rates, Risk Factors and Complications of Surgically Treated Metastatic Disease of The Spine: A Retrospective Study of A Single Center Experience from Southern Malaysia |
| NMRR-23-02300-VAX | Knowledge, Attitude and Practice of Hand Hygiene among Oncology Nurses in Hospital Sultan Ismail Johor |
| NMRR-23-02239-S4H | Evaluation on The Usage Pattern of Human Albumin at Hospital Sultan Ismail Petra Kuala Krai (HSIP) |
| NMRR-23-02127-8M2 | Analgesics Prescribing Patterns among Chronic Non-Cancer Pain in Pain Clinic. |
| NMRR-23-02504-O1A | An Assessment of Analgesic Use and Adequacy of Pain Management among Cancer Patients |
| NMRR-23-02142-T0I |
Job Satisfaction of Pharmacy Professionals Working in Hospital Sultan Ismail, Johor Bahru (HSIJB) |
| NMRR-23-02579-3AG | A 10 Years Retrospective Cross-Sectional Study on Allopurinol Induced Cutaneous Adverse Drug Reactions (cADR) in Hospital Sultan Ismail, Johor Bahru. |
| NMRR-23-02369-B3U | A Validation Study on Knowledge, Attitude, and Practice of Primary Healthcare Doctors on E-cigarette Use (KAP-ECIG) |
| NMRR-23-02237-B85 | The Role of Geriatric Clinical Pharmacist in Reducing Anticholinergic Burden among Hospitalized Geriatric Patients in Malaysia |
| NMRR-23-02081-ND2 | Defining the Gaps of Paediatric Non-Hodgkin’s Lymphoma to Improve the Outcome – A Retrospective Study in a Single Institution at Hospital Sultan Ismail, Johor Bahru |
| NMRR-23-02122-APR | Knowledge and Practice of Diabetes Self-management During Ramadan Among Fasting Muslim Patients with Type 2 Diabetes Mellitus (T2DM) in Klinik Kesihatan Ulu Tiram (KKUT) |
| NMRR-23-02378-CUK | D-dimer/ Platlet Ratio as a Prognostic Clinical Biomarker in COVID-19, a Retrospective Single Centre Cohort Study |
| NMRR-23-02768-4EB | Obesity and Mode of Delivery with Its Complications Among Primigravida In A Tertiary Hospital |
| NMRR-23-02551-I3R | Added Survival Benefit of Palliative Whole Brain Radiotherapy in Non-Small Cell Lung Cancer: An External Validation and Model Updating of a Prediction Model |
| NMRR-18-2943-43568 | Multi-center, double-blind, randomized, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of a single intravenous dose of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity |
| NMRR-19-61-45889 | An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP) |
| NMRR-19-3561-51836 | Effisayil 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in preventing generalized pustular psoriasis (GPP) flares in patients with history of GPP |
| NMRR-21-1299-59350 | A non-interventional, international, multicentre study to characterise the clinical characteristics, disease burden, and unmet medical needs of Generalized Pustular Psoriasis (GPP) patients |
| NMRR-23-00181-LIX | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. |
| NMRR-23-01937-CT2 | An Open-label, Multicenter, Single-arm, Post-marketing Trial (in Select Countries) to Evaluate Efficacy and Safety and the Impact of Immunogenicity on Efficacy, Safety, and Pharmacokinetics of Spesolimab i.v. in Treatment of Patients With Generalized Pustular Psoriasis Presenting With a Recurrent Flare Following Their Initial GPP Flare Treatment With Spesolimab i.v. |
| NMRR-24-00682-HGY | Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS) |
| NMRR-21-02221-Q9B | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) |
| NMRR-13-527-16490 | A phase 3, randomized, double blind trial of pegylated liposomal doxorubicin (PLD) plus AMG 386 or placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer |
| NMRR-24-00686-H2S | A Randomized, Double-Blind Study to compare Efficacy, Safety and Pharmacokinetics between ABP 234 and Pembrolizumab (Keytruda) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer |
| NMRR-23-00177-JFG | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) |
| NMRR-23-01900-2NS | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) |
| NMRR-24-00685-O6K | A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy (PK-SS) |
| NMRR-20-1387-55481 | Developing a policy to reduce the salt content of food consumed outside the home in Malaysia |
| NMRR-20-1979-56344 | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NMRR-18-2962-44838 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer |
| NMRR-20-1544-55704 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
| NMRR-20-1642-55827 | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) |
| NMRR-21-1438-58702 | A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy |
| NMRR-13-723-16779 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES |
| NMRR-11-1058-10123 | A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES |
| NMRR-13-1335-18861 | A prospective, multicenter, randomized, double blind, placebo controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC) |
| NMRR-19-411-46412 | A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with lung cancer |
| NMRR-21-1903-61142 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis |
| NMRR-21-1918-61166 | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis |
| NMRR-23-03315-JDS | A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of AP063 to Herceptin® in Subjects with HER2+ Breast Cancer |
| NMRR-20-2165-56279 | A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NMRR-17-658-35126 | A two-part phase 2/3 multicenter, double-blind, randomized, placebo-controlled study of Varlitinib plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with HER1/HER2 co-expressing advanced or metastatic gastric cancer without prior exposure to systemic therapy |
| NMRR-18-236-40172 | A phase 1, open-label, dose escalation and expansion study of pf-06801591 in patients with locally advanced or metastatic melanoma, squamous cell head and neck cancer, ovarian cancer, sarcoma, non-small cell lung cancer, urothelial carcinoma or other solid tumors |
| NMRR-23-00606-M4P | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer |
| NMRR-24-01672-AM0 | A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) |
| NMRR-23-03196-DT2 | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics of GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU Authorized Keytruda® in Participants With Stage II and III Melanoma Requiring Adjuvant Treatment With Pembrolizumab |
| NMRR-23-03248-ADQ | A Randomized, Double-blind, Parallel-group Study to Compare Efficacy, Safety, and Immunogenicity of GME751 (Proposed Pembrolizumab Biosimilar) and EU-authorized Keytruda® in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) |
| NMRR-24-01063-NW7 | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of JPB898 (Proposed Nivolumab Biosimilar) and US-licensed and EU-authorized Opdivo® in Combination with Yervoy® in Participants with Untreated Advanced (Unresectable/Metastatic) Melanoma |
| NMRR-21-688-58898 | A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination with Platinum+Pemetrexed Chemotherapy in Subjects with First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer |
| NMRR-18-2794-44446 | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer |
| NMRR-15-345-25211 | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer |
| NMRR-15-844-26183 | MONALEESA-3: A randomized double-blind, placebo controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment |
| NMRR-21-1256-60314 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
| NMRR-17-691-35276 | Pazopanib Real-World Assessment of Clinical Effectiveness and Safety in Patients Who Have Undergone Treatment in Different Settings in Advanced Renal Cell Carcinoma; A Prospective, Non-Interventional, Observational Study |
| NMRR-19-1566-48532 | An open label, single arm, multicentre study to assess the clinical efficacy and safety of lynparza (Olaparib) tablets maintenance monotherapy in platinum sensitive relapsed ovarian cancer patients who are in complete or partial re-sponse following platinum based chemotherapy (L-MOCA) |
| NMRR-20-1009-54718 | Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) |
| NMRR-18-210-40058 | A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib |
| NMRR-23-03349-8MF | A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) |
| NMRR-23-01008-V4J | A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence. |
| NMRR-20-3081-57424 | SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease |
| NMRR-23-02849-KF4 | A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (CAMBRIA-2) |
| NMRR-22-00091-LJ7 | A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8) |
| NMRR-23-03325-QCO | A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) |
| NMRR-23-03326-JIO | A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. |
| NMRR-22-01342-1BL | A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation |
| NMRR-13-751-17093 | A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients |
| NMRR-22-02352-2JT | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations |
| NMRR-23-00642-NZG | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 |
| NMRR-23-00528-1QF | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 |
| NMRR-17-2410-37653 | Disease Burden and Outcome Measures of Patients with Thalassaemia in Malaysia |
| NMRR-20-2206-56826 | Phase II Study to assess the efficacy of Talazoparib in Asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) |
| NMRR-17-142-34112 | A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer's disease |
| NMRR-19-176-46299 | A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing The Safety And Efficacy Of Upadacitinib To Dupilumab In Adult Subjects With Moderate To Severe Atopic Dermatitis |
| NMRR-20-1072-54683 | A Phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046 |
| NMRR-20-2807-57057 | Phase II/III Randomized, Controlled Clinical Study of AlloStim® VS. Physician's Choice in Asian Subjects with Advanced Hepatocellular Carcinoma |
| NMRR-24-00673-8J0 | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer |
| NMRR-19-1782-49278 | A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma |
| NMRR-23-02402-M5R | A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors |
| NMRR-23-03690-EFC | A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy |
| NMRR-23-03691-C7B | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) |
| NMRR-20-2330-56789 | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) |
| NMRR-20-3015-56987 | A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy |
| NMRR-15-1679-27699 | A phase III randomized open-label study of single agent pembrolizumab vs physicians' choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy (KEYNOTE-181) |
| NMRR-15-1107-26149 | A Phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
| NMRR-21-1587-60545 | Marker Assisted Selective ThErapy in Rare cancers: Knowledge database Establishing registrY Protocol |
| NMRR-23-00105-GM3 | Factors Associated With Fear of Progression Among Breast Cancer Patients in Johor State |
| NMRR-24-00798-OQ3 | Indirect Cost Estimation and Health Related Quality of Life among Patients with Generalised Pustular Psoriasis in Malaysia: A Multi-centred Study |
| NMRR-21-1063-59197 | LOCAL BRAND TUBE EVALUATION IN HAEMATOLOGY TEST, HOSPITAL SULTAN ISMAIL |
| NMRR-18-544-40614 | Clinical Validation of the Venn Ovarian CAncer Liquid Biopsy: VOCAL Study |
| NMRR-14-1501-23172 | Efficacy Of Partially Hydrolysed Guar Gum (PHGG) In Reducing Risk Of Diarrhea In Cancer Patient On Pelvic Radiation |
| NMRR-19-943-47628 | A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer |
| NMRR-23-02384-GO9 | A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% |
| NMRR-23-02385-1EU | A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels |
| NMRR-23-02859-7SS | A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in Subjects with Metastatic Nonsquamous Non-small Cell Lung Cancer. |
| NMRR-15-1717-26338 | A Pivotal Pharmacokinetic Bioequivalence Study Comparing Generic to Reference Liposome-Encapsulated Doxorubicin Hydrochloride in Subjects with Epithelial Ovarian Carcinoma Who Have Failed Platinum-Based Chemotherapy |
| NMRR-12-1158-13954 | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease |
| NMRR-14-1486-23103 | An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia |
| NMRR-23-00104-V4R | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer |
| NMRR-23-03347-RHS | A Phase III, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate The Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansice for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy |
| NMRR-24-00349-F5H | A Phase 1b/2, Open-Label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer |
| NMRR-19-3681-52367 | A phase III, randomized, double-blind study to assess the efficacy and safety of lazertinib versus gefitinib as the first-line treatment in patients with epidermal growth factor receptor sensitizing mutation positive, locally advanced or metastatic non-small cell lung cancer |
| NMRR-15-2250-28699 | A Phase III, Open-Label, Multicenter, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel In Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy |
| NMRR-14-785-21940 | Randomized, Double-blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer - A Phase III Trial |
List of Publications associated with CRC HSIJB
- Media Framing on News of The Hartal Doktor Kontrak (HDK) Movement in Malaysia: A Quantitative Content Analysis of Two Malaysian Newspapers
- Norehan Jinah , Kun Yun Lee, Nor Haniza Zakaria, Nursyahda Zakaria & Munirah Ismail
Scope of Training and Services
CRC HSIJB offers various services to external and local investigators in line with our vision and missions. Overall, there are three main categories of services provided by us upon request and yearly planning (training)
List of trainings:
- GCP certification/refresher
- Research related workshop/courses
- Student internship training
Consultation:
- Research Consultation Clinic (RCC)
- NMRR registration/troubleshoot
- Sample size calculation
- Statistical analysis
Support for Research Projects
- Study coordination for ISR/IIR
- Clinical Trial Centre
- CRC Facility (Medical Equipments)
Research Facilities
CRC Hospital Sultan Ismail, Johor Bahru, Johor
Clinical Research Centre
Level 2
Hospital Sultan Ismail
Jalan Mutiara Emas Utama
Taman Mount Austin
81100 Johor Bahru, Johor
Main Phone: +60124105672
Email: drmunirah@hsi.gov.my (Dr. Munirah Ismail)
